신경혈관 기기 시장 규모, 점유율, 동향 분석 보고서 : 기기별, 치료 용도별, 사이즈별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)
Neurovascular Devices Market Size, Share & Trends Analysis Report By Device, By Therapeutic Applications, By Size, By End-use, By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1790284
리서치사
:
Grand View Research
발행일
:
2025년 07월
페이지 정보
:
영문 110 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
neurovascular device market summary
신경혈관 장치 세계 시장 규모는 2024년에 73억 4,000만 달러로 평가되었습니다. 2033년에는 119억 1,000만 달러에 달하고, 2025-2033년 5.48%의 성장률을 보일 것으로 예측됩니다. 이 시장을 주도하는 요인은 신경혈관질환의 유병률 증가, 의료기술의 발전, 최소침습적 시술에 대한 관심 증가입니다.
뇌졸중, 뇌동맥류, 동정맥 기형(AVM)과 같은 질환이 흔해지면서 효과적인 치료 옵션에 대한 수요도 증가하고 있습니다. 뇌졸중, 동맥류 등 신경혈관질환의 유병률 증가는 신경혈관기기 산업의 큰 원동력이 되고 있습니다. 혈전 회수 장치, 마이크로카테터, 유로 전환 코일 등 다양한 신경혈관 장치가 이러한 질환의 치료에 이용되고 있습니다. 세계뇌졸중기구(WSO)가 발표한 'Global Stroke Fact Sheet 2024'에 따르면, 매년 1,200만 명 이상의 뇌졸중이 새롭게 발생하며, 전 세계 인구의 약 25%가 일생 동안 뇌졸중을 경험하게 된다고 합니다.
뇌졸중 등 신경혈관질환의 부담이 크게 증가하고 있어 혈전 회수장치, 흡입장치 등 신경혈전 제거장치 등 신경혈전 제거장치 수요를 촉진할 것으로 예측됩니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 신경혈관 기기 변수, 동향, 범위
시장 계통 전망
시장 역학
시장 성장 촉진요인 분석
시장 성장 억제요인 분석
시장 기회 분석
시장이 해결해야 할 과제 분석
신경혈관 기기 분석 툴
업계 분석 - Porter의 Five Forces 분석
PESTEL 분석
제4장 신경혈관 기기 시장 : 부문 분석, 기기별, 2021년-2033년
정의와 범위
기기별 시장 점유율 분석, 2024년 및 2033년
세계의 신경혈관 기기 시장(기기별, 2021-2033년)
시장 규모와 예측 및 동향 분석, 2021-2033년
제5장 신경혈관 기기 시장 : 부문 분석, 치료 용도별, 2021년-2033년
정의와 범위
치료 용도별 시장 점유율 분석, 2024년 및 2033년
세계의 신경혈관 기기 시장(치료 용도별, 2021-2033년)
시장 규모와 예측 및 동향 분석, 2021-2033년
제6장 신경혈관 기기 시장 : 부문 분석, 사이즈별, 2021년-2033년
정의와 범위
사이즈별 시장 점유율 분석, 2024년 및 2033년
세계의 신경혈관 기기 시장(사이즈별, 2021-2033년)
시장 규모와 예측 및 동향 분석, 2021-2033년
제7장 신경혈관 기기 시장 : 부문 분석, 최종 용도별, 2021년-2033년
정의와 범위
최종 용도별 시장 점유율 분석, 2024년 및 2033년
세계의 신경혈관 기기 시장(최종 용도별, 2021-2033년)
시장 규모와 예측 및 동향 분석, 2021-2033년
제8장 신경혈관 기기 시장 : 지역 추정·동향 분석
지역 대시보드
시장 규모, 예측 동향 분석, 2021-2033년 :
북미
유럽
영국
독일
프랑스
이탈리아
스페인
노르웨이
스웨덴
덴마크
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
쿠웨이트
제9장 경쟁 구도
주요 시장 진출기업의 최근 동향과 영향 분석
기업/경쟁 분류
혁신기업
벤더 구도
주요 유통업체 및 채널 파트너 리스트
주요 고객
2024년 세계 주요 기업의 시장 점유율 분석
Medtronic
Stryker
Terumo Corporation
Penumbra, Inc.
Johnson & Johnson and its affiliates
MicroPort Scientific Corporation
Acandis GmbH
ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
NeuroSafe Medical Co., Ltd.
Rapid Medical
Evasc Neurovascular Enterprises
Lepu Medical Technology(Beijing) Co., Ltd.
phenox GmbH
히트맵 분석/기업 시장 현황 분석
2024년 기업의 시장 점유율 예측 분석
기타 주요 시장 기업 리스트
LSH
영문 목차
Neurovascular Devices Market Summary
The global neurovascular devices market size was estimated at USD 7.34 billion in 2024 and is projected to reach USD 11.91 billion by 2033, growing at a CAGR of 5.48% from 2025 to 2033. The market is driven by the rising prevalence of neurovascular disorders, advancements in medical technology, and an increasing focus on minimally invasive procedures.
As conditions such as stroke, cerebral aneurysms, and Arteriovenous Malformations (AVM) become more common, the demand for effective treatment options also increases. The increasing prevalence of neurovascular diseases such as strokes and aneurysms is a major driving force behind the neurovascular devices industry. Various neurovascular devices, including clot retrieval devices, microcatheters, and flow diversion coils, are utilized to treat these conditions. According to the Global Stroke Fact Sheet 2024 published by the World Stroke Organization (WSO), more than 12 million new strokes occur annually, and about 25% of the global population will experience a stroke in their lifetime.
The burden of neurovascular disorders, such as strokes, is increasing significantly, which is anticipated to propel the demand for neurovascular devices such as neurothrombectomy devices like clot retrievers and suction devices, among others.
Global Neurovascular Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurovascular devices market report based on the device, therapeutic application, size, end-use, and region:
Device Outlook (Revenue, USD Million, 2021 - 2033)
Cerebral Embolization and Aneurysm Coiling Devices
Embolic coils
Flow diversion devices
Liquid embolic agents
Cerebral Angioplasty and Stenting Systems
Carotid artery stents
Embolic protection systems
Neurothrombectomy Devices
Clot retrieval devices
Suction devices/aspiration catheters
Vascular snares
Support Devices
Micro catheters
Micro guidewires
Trans Radial Access Devices
Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
Stroke
Cerebral Artery
Cerebral Aneurysm
Aneurysmal Subarachnoid Hemorrhage
Others
Others
Size (in Inches) Outlook (Revenue, USD Million, 2021 - 2033)
0.027"
0.021"
0.071"
0.017"
0.019"
0.013"
0.058"
0.068"
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Specialty Clinics
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Italy
Spain
Norway
Denmark
Sweden
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
KuwaitTable of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Device
1.2.2. Therapeutic Applications
1.2.3. Size
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Neurovascular Devices Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Neurovascular Diseases
3.2.1.2. Technological Advancements in Neurovascular Devices
3.2.1.3. Rising Number of Awareness Initiatives
3.2.1.4. Increasing Demand for Minimally Invasive Procedures
3.2.2. Market Restraint Analysis
3.2.2.1. Product Recalls
3.2.2.2. High Treatment Cost Associated with Neurovascular Disorders
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Number of Clinical Trials
3.2.3.2. Launches of Novel Products
3.2.3.3. Increasing Research & Development Activities
3.2.4. Market Challenge Analysis
3.2.4.1. Shortage of Skilled Professionals
3.2.4.2. Potential Complications & Risks associated with Neurovascular Devices
3.3. Neurovascular Devices Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Neurovascular Devices Market: Segment Analysis, By Device, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Device Market Share Analysis, 2024 & 2033
4.3. Global Neurovascular Devices Market, by Device, 2021 to 2033
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4.1. Cerebral Embolization and Aneurysm Coiling Devices
4.4.1.1. Cerebral embolization and aneurysm coiling devices market, 2021 - 2033 (USD Million)
4.4.1.2. Embolic coils
4.4.1.2.1. Embolic coils market, 2021 - 2033 (USD Million)
4.4.1.3. Flow diverters
4.4.1.3.1. Flow diverters market, 2021 - 2033 (USD Million)
4.4.1.4. Liquid embolic agents
4.4.1.4.1. Liquid embolic agents market, 2021 - 2033 (USD Million)
4.4.2. Cerebral angioplasty and stenting systems
4.4.2.1. Cerebral angioplasty and stenting systems market, 2021 - 2033 (USD Million)
4.4.2.2. Carotid Artery Stents
4.4.2.2.1. Carotid artery stents market, 2021 - 2033 (USD Million)
4.4.2.3. Embolic Protection Devices
4.4.2.3.1. Embolic protection systems devices market, 2021 - 2033 (USD Million)
4.4.3. Neurothrombectomy devices
4.4.3.1. Neurothrombectomy devices market, 2021 - 2033 (USD Million)
4.4.3.2. Clot Retrieval Devices
4.4.3.2.1. Clot retrieval devices market, 2021 - 2033 (USD Million)
4.4.3.3. Suction Devices
4.4.3.3.1. Suction devices market, 2021 - 2033 (USD Million)
4.4.3.4. Vascular Snares
4.4.3.4.1. Vascular snares market, 2021 - 2033 (USD Million)
4.4.4. Support devices
4.4.4.1. Support devices market, 2021 - 2033 (USD Million)
4.4.4.2. Micro Catheters
4.4.4.2.1. Micro catheters market, 2021 - 2033 (USD Million)
4.4.4.3. Micro Guidewires
4.4.4.3.1. Micro guidewires market, 2021 - 2033 (USD Million)
4.4.5. Trans Radial Access Devices
4.4.5.1. Trans radial access devices market, 2021 - 2033 (USD Million)
Chapter 5. Neurovascular Devices Market: Segment Analysis, By Therapeutic Applications, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Therapeutic Applications Market Share Analysis, 2024 & 2033
5.3. Global Neurovascular Devices Market, by Therapeutic Applications, 2021 to 2033
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.4.1. Stroke
5.4.1.1. Stroke market, 2021 - 2033 (USD Million)
5.4.2. Cerebral artery stenosis
5.4.2.1. Cerebral artery stenosis market, 2021 - 2033 (USD Million)
5.4.3. Cerebral aneurysm
5.4.3.1. Cerebral aneurysm market, 2021 - 2033 (USD Million)
5.4.3.2. Aneurysmal Subarachnoid Hemorrhage
5.4.3.2.1. Aneurysmal subarachnoid hemorrhage market, 2021 - 2033 (USD Million)
5.4.3.3. Others
5.4.3.4. Others market, 2021 - 2033 (USD Million)
5.4.4. Others
5.4.4.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. Neurovascular Devices Market: Segment Analysis, By Size, 2021 - 2033 (USD Million)
6.1. Definition and Scope
6.2. Size Market Share Analysis, 2024 & 2033
6.3. Global Neurovascular Devices Market, by Size, 2021 to 2033
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
6.4.1. 0.027"
6.4.1.1. 0.027" market, 2021 - 2033 (USD Million)
6.4.2. 0.021"
6.4.2.1. 0.021" market, 2021 - 2033 (USD Million)
6.4.3. 0.071"
6.4.3.1. 0.071" market, 2021 - 2033 (USD Million)
6.4.4. 0.017"
6.4.4.1. 0.017" market, 2021 - 2033 (USD Million)
6.4.5. 0.019"
6.4.5.1. 0.019" market, 2021 - 2033 (USD Million)
6.4.6. 0.013"
6.4.6.1. 0.013" market, 2021 - 2033 (USD Million)
6.4.7. 0.058"
6.4.7.1. 0.058" market, 2021 - 2033 (USD Million)
6.4.8. 0.068"
6.4.8.1. 0.068" market, 2021 - 2033 (USD Million)
6.4.9. Others
6.4.9.1. Others market, 2021 - 2033 (USD Million)
Chapter 7. Neurovascular Devices Market: Segment Analysis, By End Use, 2021 - 2033 (USD Million)
7.1. Definition and Scope
7.2. End Use Market Share Analysis, 2024 & 2033
7.3. Global Neurovascular Devices Market, by End Use, 2021 to 2033
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
7.4.1. Hospital
7.4.1.1. Hospital market, 2021 - 2033 (USD Million)
7.4.2. Specialty clinics
7.4.2.1. Specialty clinics market, 2021 - 2033 (USD Million)
7.4.3. Others
7.4.3.1. Others market, 2021 - 2033 (USD Million)
Chapter 8. Neurovascular Devices Market: Regional Estimates & Trend Analysis
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2021 to 2033, (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2021 to 2033, (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2021 to 2033, (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Innovators
9.4. Vendor Landscape
9.5. List of key distributors and channel partners
9.6. Key customers
9.7. Global Key company market share analysis, 2024
9.7.1. Medtronic
9.7.1.1. Company overview
9.7.1.2. Financial performance
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.7.2. Stryker
9.7.2.1. Company overview
9.7.2.2. Financial performance
9.7.2.3. Product benchmarking
9.7.2.4. Strategic initiatives
9.7.3. Terumo Corporation
9.7.3.1. Company overview
9.7.3.2. Financial performance
9.7.3.3. Product benchmarking
9.7.3.4. Strategic initiatives
9.7.4. Penumbra, Inc.
9.7.4.1. Company overview
9.7.4.2. Financial performance
9.7.4.3. Product benchmarking
9.7.4.4. Strategic initiatives
9.7.5. Johnson & Johnson and its affiliates
9.7.5.1. Company overview
9.7.5.2. Financial performance
9.7.5.3. Product benchmarking
9.7.5.4. Strategic initiatives
9.7.6. MicroPort Scientific Corporation
9.7.6.1. Company overview
9.7.6.2. Financial performance
9.7.6.3. Product benchmarking
9.7.6.4. Strategic initiatives
9.7.7. Acandis GmbH
9.7.7.1. Company overview
9.7.7.2. Financial performance
9.7.7.3. Product benchmarking
9.7.7.4. Strategic initiatives
9.7.8. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
9.7.8.1. Company overview
9.7.8.2. Financial performance
9.7.8.3. Product benchmarking
9.7.8.4. Strategic initiatives
9.7.9. NeuroSafe Medical Co., Ltd.
9.7.9.1. Company overview
9.7.9.2. Financial performance
9.7.9.3. Product benchmarking
9.7.9.4. Strategic initiatives
9.7.10. Rapid Medical
9.7.10.1. Company overview
9.7.10.2. Financial performance
9.7.10.3. Product benchmarking
9.7.10.4. Strategic initiatives
9.7.11. Evasc Neurovascular Enterprises
9.7.11.1. Company overview
9.7.11.2. Financial performance
9.7.11.3. Product benchmarking
9.7.11.4. Strategic initiatives
9.7.12. Lepu Medical Technology(Beijing)Co., Ltd.
9.7.12.1. Company overview
9.7.12.2. Financial performance
9.7.12.3. Product benchmarking
9.7.12.4. Strategic initiatives
9.7.13. phenox GmbH
9.7.13.1. Company overview
9.7.13.2. Financial performance
9.7.13.3. Product benchmarking
9.7.13.4. Strategic initiatives
9.8. Heat Map Analysis/ Company Market Position Analysis
9.9. Estimated Company Market Share Analysis, 2024
9.10. List of Other Key Market Players
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Device
1.2.2. Therapeutic Applications
1.2.3. Size
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Neurovascular Devices Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Neurovascular Diseases
3.2.1.2. Technological Advancements in Neurovascular Devices
3.2.1.3. Rising Number of Awareness Initiatives
3.2.1.4. Increasing Demand for Minimally Invasive Procedures
3.2.2. Market Restraint Analysis
3.2.2.1. Product Recalls
3.2.2.2. High Treatment Cost Associated with Neurovascular Disorders
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Number of Clinical Trials
3.2.3.2. Launches of Novel Products
3.2.3.3. Increasing Research & Development Activities
3.2.4. Market Challenge Analysis
3.2.4.1. Shortage of Skilled Professionals
3.2.4.2. Potential Complications & Risks associated with Neurovascular Devices
3.3. Neurovascular Devices Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Neurovascular Devices Market: Segment Analysis, By Device, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Device Market Share Analysis, 2024 & 2033
4.3. Global Neurovascular Devices Market, by Device, 2021 to 2033
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
4.4.1. Cerebral Embolization and Aneurysm Coiling Devices
4.4.1.1. Cerebral embolization and aneurysm coiling devices market, 2021 - 2033 (USD Million)
4.4.1.2. Embolic coils
4.4.1.2.1. Embolic coils market, 2021 - 2033 (USD Million)
4.4.1.3. Flow diverters
4.4.1.3.1. Flow diverters market, 2021 - 2033 (USD Million)
4.4.1.4. Liquid embolic agents
4.4.1.4.1. Liquid embolic agents market, 2021 - 2033 (USD Million)
4.4.2. Cerebral angioplasty and stenting systems
4.4.2.1. Cerebral angioplasty and stenting systems market, 2021 - 2033 (USD Million)
4.4.2.2. Carotid Artery Stents
4.4.2.2.1. Carotid artery stents market, 2021 - 2033 (USD Million)
4.4.2.3. Embolic Protection Devices
4.4.2.3.1. Embolic protection systems devices market, 2021 - 2033 (USD Million)
4.4.3. Neurothrombectomy devices
4.4.3.1. Neurothrombectomy devices market, 2021 - 2033 (USD Million)
4.4.3.2. Clot Retrieval Devices
4.4.3.2.1. Clot retrieval devices market, 2021 - 2033 (USD Million)
4.4.3.3. Suction Devices
4.4.3.3.1. Suction devices market, 2021 - 2033 (USD Million)
4.4.3.4. Vascular Snares
4.4.3.4.1. Vascular snares market, 2021 - 2033 (USD Million)
4.4.4. Support devices
4.4.4.1. Support devices market, 2021 - 2033 (USD Million)
4.4.4.2. Micro Catheters
4.4.4.2.1. Micro catheters market, 2021 - 2033 (USD Million)
4.4.4.3. Micro Guidewires
4.4.4.3.1. Micro guidewires market, 2021 - 2033 (USD Million)
4.4.5. Trans Radial Access Devices
4.4.5.1. Trans radial access devices market, 2021 - 2033 (USD Million)
Chapter 5. Neurovascular Devices Market: Segment Analysis, By Therapeutic Applications, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Therapeutic Applications Market Share Analysis, 2024 & 2033
5.3. Global Neurovascular Devices Market, by Therapeutic Applications, 2021 to 2033
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
5.4.1. Stroke
5.4.1.1. Stroke market, 2021 - 2033 (USD Million)
5.4.2. Cerebral artery stenosis
5.4.2.1. Cerebral artery stenosis market, 2021 - 2033 (USD Million)
5.4.3. Cerebral aneurysm
5.4.3.1. Cerebral aneurysm market, 2021 - 2033 (USD Million)
5.4.3.2. Aneurysmal Subarachnoid Hemorrhage
5.4.3.2.1. Aneurysmal subarachnoid hemorrhage market, 2021 - 2033 (USD Million)
5.4.3.3. Others
5.4.3.4. Others market, 2021 - 2033 (USD Million)
5.4.4. Others
5.4.4.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. Neurovascular Devices Market: Segment Analysis, By Size, 2021 - 2033 (USD Million)
6.1. Definition and Scope
6.2. Size Market Share Analysis, 2024 & 2033
6.3. Global Neurovascular Devices Market, by Size, 2021 to 2033
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
6.4.1. 0.027"
6.4.1.1. 0.027" market, 2021 - 2033 (USD Million)
6.4.2. 0.021"
6.4.2.1. 0.021" market, 2021 - 2033 (USD Million)
6.4.3. 0.071"
6.4.3.1. 0.071" market, 2021 - 2033 (USD Million)
6.4.4. 0.017"
6.4.4.1. 0.017" market, 2021 - 2033 (USD Million)
6.4.5. 0.019"
6.4.5.1. 0.019" market, 2021 - 2033 (USD Million)
6.4.6. 0.013"
6.4.6.1. 0.013" market, 2021 - 2033 (USD Million)
6.4.7. 0.058"
6.4.7.1. 0.058" market, 2021 - 2033 (USD Million)
6.4.8. 0.068"
6.4.8.1. 0.068" market, 2021 - 2033 (USD Million)
6.4.9. Others
6.4.9.1. Others market, 2021 - 2033 (USD Million)
Chapter 7. Neurovascular Devices Market: Segment Analysis, By End Use, 2021 - 2033 (USD Million)
7.1. Definition and Scope
7.2. End Use Market Share Analysis, 2024 & 2033
7.3. Global Neurovascular Devices Market, by End Use, 2021 to 2033
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
7.4.1. Hospital
7.4.1.1. Hospital market, 2021 - 2033 (USD Million)
7.4.2. Specialty clinics
7.4.2.1. Specialty clinics market, 2021 - 2033 (USD Million)
7.4.3. Others
7.4.3.1. Others market, 2021 - 2033 (USD Million)
Chapter 8. Neurovascular Devices Market: Regional Estimates & Trend Analysis
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2021 to 2033, (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2021 to 2033, (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2021 to 2033, (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Innovators
9.4. Vendor Landscape
9.5. List of key distributors and channel partners
9.6. Key customers
9.7. Global Key company market share analysis, 2024
9.7.1. Medtronic
9.7.1.1. Company overview
9.7.1.2. Financial performance
9.7.1.3. Product benchmarking
9.7.1.4. Strategic initiatives
9.7.2. Stryker
9.7.2.1. Company overview
9.7.2.2. Financial performance
9.7.2.3. Product benchmarking
9.7.2.4. Strategic initiatives
9.7.3. Terumo Corporation
9.7.3.1. Company overview
9.7.3.2. Financial performance
9.7.3.3. Product benchmarking
9.7.3.4. Strategic initiatives
9.7.4. Penumbra, Inc.
9.7.4.1. Company overview
9.7.4.2. Financial performance
9.7.4.3. Product benchmarking
9.7.4.4. Strategic initiatives
9.7.5. Johnson & Johnson and its affiliates
9.7.5.1. Company overview
9.7.5.2. Financial performance
9.7.5.3. Product benchmarking
9.7.5.4. Strategic initiatives
9.7.6. MicroPort Scientific Corporation
9.7.6.1. Company overview
9.7.6.2. Financial performance
9.7.6.3. Product benchmarking
9.7.6.4. Strategic initiatives
9.7.7. Acandis GmbH
9.7.7.1. Company overview
9.7.7.2. Financial performance
9.7.7.3. Product benchmarking
9.7.7.4. Strategic initiatives
9.7.8. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
9.7.8.1. Company overview
9.7.8.2. Financial performance
9.7.8.3. Product benchmarking
9.7.8.4. Strategic initiatives
9.7.9. NeuroSafe Medical Co., Ltd.
9.7.9.1. Company overview
9.7.9.2. Financial performance
9.7.9.3. Product benchmarking
9.7.9.4. Strategic initiatives
9.7.10. Rapid Medical
9.7.10.1. Company overview
9.7.10.2. Financial performance
9.7.10.3. Product benchmarking
9.7.10.4. Strategic initiatives
9.7.11. Evasc Neurovascular Enterprises
9.7.11.1. Company overview
9.7.11.2. Financial performance
9.7.11.3. Product benchmarking
9.7.11.4. Strategic initiatives
9.7.12. Lepu Medical Technology(Beijing)Co., Ltd.
9.7.12.1. Company overview
9.7.12.2. Financial performance
9.7.12.3. Product benchmarking
9.7.12.4. Strategic initiatives
9.7.13. phenox GmbH
9.7.13.1. Company overview
9.7.13.2. Financial performance
9.7.13.3. Product benchmarking
9.7.13.4. Strategic initiatives
9.8. Heat Map Analysis/ Company Market Position Analysis
9.9. Estimated Company Market Share Analysis, 2024
9.10. List of Other Key Market Players
관련자료
